Eton制药公司收购了经林业发展局批准的Galzin,用于治疗威尔逊病,在2025年Q1推出美国销售。 Eton Pharmaceuticals acquires FDA-approved Galzin for Wilson Disease, launching U.S. sales in Q1 2025.

Eton制药公司已经收购了Galzin 一种罕见的代谢紊乱 由林业发展局批准的威尔逊病治疗方法 Eton Pharmaceuticals has acquired Galzin, an FDA-approved treatment for Wilson Disease, a rare metabolic disorder. 这一举动加强了Eton对罕见疾病的关注,并定于2025年第一季度在美国开始商业化。 This move strengthens Eton's focus on rare diseases and is set to commence commercialization in the U.S. in the first quarter of 2025. 该公司计划通过其Eton Cares方案提供治疗。 Eton Cares方案提供个性化支持,并为合格病人提供零美元共同付费。 The company plans to offer the treatment through its Eton Cares program, which provides personalized support and a $0 co-pay for qualified patients.